Barclays analyst Matt Miksic maintains $Edwards Lifesciences (EW.US)$ with a buy rating, and maintains the target price at $85.
According to TipRanks data, the analyst has a success rate of 62.2% and a total average return of 7.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Edwards Lifesciences (EW.US)$'s main analysts recently are as follows:
Edwards Lifesciences reported a robust performance in sales and earnings, with the future outlook for Q4 and long-term projections up to 2025 anticipated to sustain the stock's upward trajectory.
The assessment is that it may require several more financial quarters for Edwards Lifesciences to assure investors of the stabilization of its TAVR franchise after the third-quarter report.
Expectations were subdued prior to the release of the quarterly results, and subsequent discussions regarding Q4 and future fiscal years did not dispel concerns of potential decline. Although the slowing Q4 TAVR trends are partially attributable to one-time factors, it remains challenging to counter the notion that TAVR growth may continue to decelerate in the upcoming fiscal year.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
巴克莱银行分析师Matt Miksic维持$爱德华生命科学 (EW.US)$买入评级，维持目标价85美元。
根据TipRanks数据显示，该分析师近一年总胜率为62.2%，总平均回报率为7.2%。
此外，综合报道，$爱德华生命科学 (EW.US)$近期主要分析师观点如下：
爱德华生命科学报告销售和收益表现强劲，展望未来包括第四季度和预计持续到2025年的长期预测，预计将支撑股票的上升轨迹。
评估结果是，爱德华生命科学可能需要几个更多的财季才能向投资者保证其TAVR业务在第三季度报告之后的稳定。
在季度结果发布之前，市场对预期持谨慎态度，对第四季度和未来财政年度的讨论并没有消除潜在下滑的担忧。尽管第四季度TAVR趋势放缓在一定程度上可归因于一次性因素，但难以反驳TAVR增长可能在即将到来的财政年度继续减速的观点。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
